Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Youmna Jalkh"'
Autor:
Andrew A Chen, Kelly Clark, Blake E Dewey, Anna DuVal, Nicole Pellegrini, Govind Nair, Youmna Jalkh, Samar Khalil, Jon Zurawski, Peter A Calabresi, Daniel S Reich, Rohit Bakshi, Haochang Shou, Russell T Shinohara, Alzheimer’s Disease Neuroimaging Initiative, and North American Imaging in Multiple Sclerosis Cooperative
Publikováno v:
PLoS Computational Biology, Vol 20, Iss 7, p e1012241 (2024)
Dimension reduction tools preserving similarity and graph structure such as t-SNE and UMAP can capture complex biological patterns in high-dimensional data. However, these tools typically are not designed to separate effects of interest from unwanted
Externí odkaz:
https://doaj.org/article/6dc81d154df04a90a16c0ae4b80ffc44
Publikováno v:
Frontiers in Psychology, Vol 11 (2020)
Children’s understanding of unobservable scientific entities largely depends on testimony from others, especially through parental explanations that highlight the mechanism underlying a scientific entity. Mechanistic explanations are particularly h
Externí odkaz:
https://doaj.org/article/05876ae2e29e48dda91279c0c41b7c0e
Autor:
Giovanna S. Manzano, Dylan R. Rice, Jonathan Zurawski, Youmna Jalkh, Rohit Bakshi, Farrah J. Mateen
Publikováno v:
Journal of Neuroimmunology. 379:578099
Autor:
Mahmoud A. AbdelRazek, Subhash Tummala, Fariha Khalid, Shahamat Tauhid, Youmna Jalkh, Samar Khalil, Shelley Hurwitz, Jonathan Zurawski, Rohit Bakshi
Publikováno v:
Journal of the neurological sciences. 444
Cerebral gray matter (GM) atrophy is a proposed measure of neuroprotection in multiple sclerosis (MS). Glatiramer acetate (GA) limits clinical relapses, MRI lesions, and whole brain atrophy in relapsing-remitting MS (RRMS). The effect of GA on GM atr
Autor:
Bassem Yamout, Marianne Said, Samia J. Khoury, Salem Hannoun, Ribal Haddad, Leslie Saba, Youmna Jalkh, Nabil K. El Ayoubi
Publikováno v:
Multiple Sclerosis and Related Disorders. 26:96-102
Prevention of long-term disability is the goal of therapeutic intervention in Relapsing Remitting MS (RRMS). The Bayesian Risk Estimate for MS at Onset (BREMSO) gives an individual risk score predicting disease evolution into Secondary Progressive MS